Keyphrases
Adverse Events
11%
Clinical Response
11%
Combination Therapy
11%
Dual Blockade
11%
Eastern Cooperative Oncology Group
55%
ER +
11%
Eribulin
100%
Group Status
55%
HER2+
11%
HER2-targeted Therapy
11%
Interactive Effects
11%
Leukopenia
11%
Low Risk
11%
Lymphocyte-to-monocyte Ratio
66%
Metastatic Breast Cancer
100%
Monotherapy
11%
Multivariate Analysis
11%
Neutropenia
11%
Predictive Factors
100%
Predictive Marker
22%
Prognostic Factors
100%
Protective Factors
11%
Response Predictors
11%
Restrospective
11%
Time to Treatment Failure
11%
Time-to-treatment
11%
Treatment Failure
33%
Treatment Line
22%
Triple Negative
11%
Univariate Analysis
11%
Visceral Metastases
11%
Medicine and Dentistry
Adverse Event
11%
Biological Marker
11%
Cohort Analysis
11%
Combination Therapy
11%
Leukopenia
11%
Lymphocyte
66%
Metastatic Breast Cancer
100%
Monotherapy
11%
Multivariate Analysis
11%
Neutropenia
11%
Oncology
55%
Predictive Factor
100%
Predictive Marker
22%
Prognostic Factor
100%
Protective Factor
11%
Time to Treatment
11%
Univariate Analysis
11%
Visceral Metastasis
11%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Biological Marker
11%
Cohort Study
11%
Combination Therapy
11%
Eribulin
100%
Leukopenia
11%
Metastatic Breast Cancer
100%
Monotherapy
11%
Neutropenia
11%